ArticleRegenerative therapy2025
Generation of implant-type tissue-engineered cartilage from human embryonic stem cell-derived chondrocytes.
Article in Regenerative therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Autologous cartilage transplantation has been applied clinically but its efficacy is limited by donor site morbidity, inter-donor variability, and high manufacturing costs. Primary chondrocytes also tend to dedifferentiate during expansion, which further limits their redifferentiation potential. Cartilage is weakly immunogenic and is thus an ideal tissue source for allogeneic transplantation. Allogeneic transplantation has drawn much interest due to the immune-privileged nature of cartilage and the recent success of allogeneic chondrocyte therapies. Meanwhile, human embryonic stem cells (hESCs) offer a scalable source of chondrocytes with high redifferentiation capacity. Building on the xeno-free automated chondrogenic differentiation of SEES2 hESCs in previous research, this study aims to establish an implant-type regenerative cartilage platform using hESCs for potential allogeneic transplantation. Methods: hESCs (SEES2) were differentiated into cartilage tissue using an embryoid body-based protocol and cultured on collagen-coated dishes for 60 days. Cartilage-derived chondrocytes were isolated and expanded in a monolayer. Passage 3 (P3) cells were used for pellet culture, maintained for 21 days, and analyzed using histology and biochemical assays. Gene expression was assessed by RNA sequencing. Additionally, P3 chondrocytes were seeded onto bioresorbable PGA nonwoven fabric scaffolds, implanted subcutaneously into athymic nude mice for 4 weeks, and subjected to histological and biochemical analyses. Results: Human embryonic stem cell-derived chondrocytes (hESC-Chs) were successfully isolated and expanded over 10 Conclusion: We successfully established a reproducible method for isolating and expanding chondrocytes from hESC-derived cartilage tissue. Under optimized culture conditions, these cells demonstrated the capacity for redifferentiation and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.